Bots, editor, reviewer, Administrators
13,941
edits
(STEP-HFpEF now reviewable) |
(ARTESIA now reviewable) |
||
Line 6: | Line 6: | ||
===Reviewable=== | ===Reviewable=== | ||
* 2023 {{create article link|STEP-HFpEF}}: GLP-1 agonist in HFpEF and obesity [https://www.nejm.org/doi/full/10.1056/NEJMoa2306963] | * 2023 {{create article link|STEP-HFpEF}}: GLP-1 agonist in HFpEF and obesity [https://www.nejm.org/doi/full/10.1056/NEJMoa2306963] | ||
* 2023 {{create article link|ARTESIA}}: Apixaban for stroke reduction in subclinical AF [https://www.nejm.org/doi/full/10.1056/NEJMoa2310234] | |||
===Incomplete or nonexistent=== | ===Incomplete or nonexistent=== | ||
Line 12: | Line 13: | ||
* 2023 {{create article link|ENLIVEN}}: FGF21 analogue in NASH [https://www.nejm.org/doi/full/10.1056/NEJMoa2304286] | * 2023 {{create article link|ENLIVEN}}: FGF21 analogue in NASH [https://www.nejm.org/doi/full/10.1056/NEJMoa2304286] | ||
* 2023 {{create article link|Clarity AD}}: Lecanemab in Alzheimer's disease [https://www.nejm.org/doi/full/10.1056/NEJMoa2212948] | * 2023 {{create article link|Clarity AD}}: Lecanemab in Alzheimer's disease [https://www.nejm.org/doi/full/10.1056/NEJMoa2212948] | ||
* 2023 {{create article link|AMIKINHAL}}: Inhaled amikacin to prevent ventilator-associated pneumonia [https://www.nejm.org/doi/full/10.1056/NEJMoa2310307] | * 2023 {{create article link|AMIKINHAL}}: Inhaled amikacin to prevent ventilator-associated pneumonia [https://www.nejm.org/doi/full/10.1056/NEJMoa2310307] | ||
* 2022 {{create article link|DESTINY-Breast04}}: Trastuzumab deruxtecan in previously treated HER2-Low breast cancer [https://www.nejm.org/doi/full/10.1056/NEJMoa2203690] | * 2022 {{create article link|DESTINY-Breast04}}: Trastuzumab deruxtecan in previously treated HER2-Low breast cancer [https://www.nejm.org/doi/full/10.1056/NEJMoa2203690] |